Silence Therapeutics plc Income Statement
SLN|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Silence Therapeutics plc reported $32M in revenue and $45M in net loss for FY2025. Revenue increased 46.1% from FY2024 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -22.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $31.6M | $21.7M |
| Cost of Revenue | $11.8M | $13.5M |
| Gross Profit | $31.4M | $8.2M |
| SG&A Expense | $26.9M | $25.7M |
| R&D Expense | $67.9M | $43.5M |
| Operating Income | -$63.3M | -$61.0M |
| Income Tax | $845.0K | $688.0K |
| Net Income | -$45.3M | -$50.3M |
| EPS (Basic) | -$0.33 | -$0.52 |
| EPS (Diluted) | -$0.33 | -$0.52 |
| Shares Outstanding | 141.7M | 107.8M |
| Gross Margin | 99.4% | 37.8% |
| Operating Margin | -200.1% | -281.9% |
| Profit Margin | -143.2% | -232.4% |